J Clin Pathol Qual Control.
2000 Jun;22(1):127-138.
Annual Report on External Quality Assessment in Therapeutic Drug Monitoring in Korea (1999)
- Affiliations
-
- 1Therapeutic Drug Monitoring Subcommittee, The Korean Association of Quality Assurance for Clinical Pathology, Seoul, Korea.
Abstract
- Two trials of external quality assessment for therapeutic drug monitoring (TDM) were performed in 1999. A total of two specimens were distributed. One specimen was distributed to 84 laboratories with 74 response (88.9%) in the first trial and the other specimen to 81 laboratories with 73 response (90.1%) in the second trial. In first trial, 26 test items including acetaminophen, amikacin, amitriptyline, carbamazepine, chloramphenicol, cyclosporine, digoxin, disopyramide, ethosuximide, free phenytoin, gentamicin, lidocaine, lithium, methotrexate, N-acetyl-procainamide, phenobarbital, phenytoin, primidone, procainamide, propranolol, quinidine, salicylate, theophyline, tobramycin, valproic acid and vancomycin were evaluated. In second trial, 17 items excluding amitriptyline, chloramphenicol, cyclosporine, disopyramide, free phenytoin, lidocaine, lithium, methotrexate and propranolol were evaluated. The results of two trials in 1999 were summarized as follows. 1. The percentage of laboratories able to perform TDM was less than 18% among all the members in the Korean Association of Quality Assurance for Clinical Pathology. 2. The most widely used TDM analyzer was abbott TDx system. 3. The most common test items were digoxin, phenytoin, phenobarbital, carbamazepine, theophylline and valproic acid.